CPhI Online

- Biopharma News

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Samsung Biologics has attained ISO 22301 certification — the international standard for business continuity management — for additional business operations.

Managing to ISO 22301 levels is itself a rigorous endeavor and achieving certification is an indication of an organization's robust and sustained ability to prevent, prepare for, respond to, and recover from unexpected and disruptive incidents.

In 2018, Samsung Biologics was the first to achieve ISO 22301 certification in the biologics CMO industries for Plant 1, Plant 2, and support functions as validated by the British Standard Institution (BSI) certification body. Samsung subsequently achieved ISO certification for drug product in 2019, and the latest certification confirms Samsung's business continuity management system (BCMS) and operational resiliency for Plant 3, biotesting and quality control services, and an extended line of small-scale operations in 2020 according to ISO standards.

Expanding its ISO 22301 certification is expected to build greater trust with Samsung for clients who are seeking a reliable manufacturing partner to ensure a stable supply of life-saving drugs. In light of the current pandemic and the race to develop and mass-produce COVID-19 therapies, business continuity and disaster preparedness are growing in importance.

As a part of the BCMS responding to the pandemic, Samsung Biologics established war rooms to proactively manage its global supply chain and employee safety to prevent any potential disruptions to cGMP manufacturing and other business operations.

Read More

Related Content